The Billion-Dollar Molecule is a book by journalist Barry Werth about the founding and early research efforts of the American biotechnology company Vertex Pharmaceuticals, which was founded in 1989 by Joshua Boger and was among the first biotechnology companies to adopt an explicit strategy of rational drug design as opposed to techniques based on combinatorial chemistry.
Cayman Chemical Company is an American biotechnology company founded in 1980, headquartered in Ann Arbor, MI.
 The company provides chemicals that are used primarily by universities and pharmaceutical companies for research and the development of medicines.
 The company is also known as a provider of reference standards to state and federal crime labs for use in the detection of rapidly evolving designer drugs.
 Small quantities of these known reference standards are analyzed using mass spectrometry and gas chromatography techniques to match against forensic evidence, usually confiscated by law enforcement, or forensic toxicological evidence collected in the form of biological samples such as urine, blood, or tissue.
Icos Corporation (trademark ICOS) was an American biotechnology company and the largest biotechnology company in the U.S. state of Washington, before it was sold to Eli Lilly and Company in 2007.
 It was founded in 1989 by David Blech, Isaac Blech, Robert Nowinski, and George Rathmann, a pioneer in the industry and Chief Executive Officer (CEO) and co-founder of Amgen, Icos focused on the development of drugs to treat inflammatory disorders.
 During its 17-year history, the company conducted clinical trials of twelve drugs, three of which reached the last phase of clinical trials.
 Icos also manufactured antibodies for other biotechnology companies.
Romidepsin, also known as Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs).
 Romidepsin is a natural product obtained from the bacterium "Chromobacterium violaceum", and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis.
 It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs.
 Romidepsin is branded and owned by Gloucester Pharmaceuticals, now a part of Celgene.
Sanofi Genzyme is an American biotechnology company based in Cambridge, Massachusetts.
 Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi.
 In 2010, Genzyme was the world’s third-largest biotechnology company which employed more than 11,000 people around the world.
 As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories.
 Its products are also sold in 90 countries.
 In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products in the market.
 In 2006 and 2007, Genzyme was named one of Fortune Magazine’s “100 Best Companies to Work for”.
 The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations.
 In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America’s leading innovators.
Randal J. Kirk (born March 1, 1954) is an American businessman and investor in pharmaceuticals and biotechnology.
 Kirk is the chairman and chief executive officer of Intrexon (NYSE: XON), a biotechnology company.
 Kirk started as a lawyer, but is best known for his investments in pharmaceutical and biotech companies.
 In addition to high-profile sales of New River Pharmaceuticals, Inc., and Clinical Data, Inc, Kirk also founded investment firm Third Security, LLC, and has held board seats with biotech companies, such as Scios, Inc., and ZIOPHARM Oncology.
 He is a billionaire and is listed on the Forbes 400.
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders.
 It is incorporated in Delaware and headquartered in Summit, New Jersey.
 The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients.
 Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
 Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals.
 Vidaza is approved for the treatment of patients with MDS.
Bionovo (NASDAQ: BNVI.OB) was an American biotechnology company focused on the discovery and development of botanically derived treatments for women's health and cancer based in Emeryville, California.
 The company had two drug candidates in U.S. Food and Drug Administration (FDA) clinical trials- Menerba (formerly known as MF101) a selective estrogen receptor beta agonist for hot flashes associated with menopause and Bezielle (formerly BZL101) for advanced breast cancer.
 The company has ceased activity and its stock, although still listed, not moved from 0,00 USD since the end of 2012.
 No statement has been made by the management, nor any indication has been given that the company is still active.
 The last press statement was about the sell of all the technical equipment and lay off of 90% of the staff.
 In short words, the company is as good as bankrupted and shut down, although the management never officially admitted it.
Daiichi Sankyo Company, Limited (第一三共株式会社 , Daiichi Sankyō Kabushiki-kaisha ) is a global pharmaceutical company and the second largest pharmaceutical company in Japan.
 It achieved JPY 1,148.2 billion in revenue in 2013.
 The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India.
 Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.
John C. Martin (born 1951) is the executive chairman (2016-) and former CEO (1996-2016) of the American biotechnology company Gilead Sciences.
 He joined Gilead Sciences in 1990 as Vice President for Research and Development.
 In addition to helping developing other drugs such as Atripla (for HIV/AIDS), Martin led the team that developed Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C.
 He is the recipient of a number of awards, including the Biotechnology Heritage Award (2017).

Question: What American biotechnology company is part of Gloucester Pharmaceuticals?
Answer: Celgene